Elagolix, Estradiol, And Norethindrone

Introduction Overview

Generic Name

elagolix, estradiol, and norethindrone

Brand Name

Oriahnn

Dosage Form

Oral capsules (two types: white/yellow capsule and white/blue capsule)

Drug Class

Sex hormone combinations

Pharmacokinetics

Absorption:
Elagolix, estradiol, and norethindrone in Oriahnn are administered orally as capsules with a distinct morning and evening dosing regimen. Elagolix is rapidly absorbed from the gastrointestinal tract with peak plasma concentrations achieved within approximately 1–2 hours after oral administration. Estradiol and norethindrone also exhibit rapid absorption after oral dosing, with estradiol showing peak plasma concentrations within 4–6 hours, and norethindrone within 1–2 hours. The bioavailability of estradiol is limited by first-pass hepatic metabolism, while norethindrone shows moderate bioavailability due to similar hepatic effects. Food effects on absorption are minimal, and administration can occur with or without food. Clinical implications include the importance of consistent dosing times to maintain steady-state plasma levels for therapeutic efficacy.

Distribution:
Elagolix exhibits a moderate volume of distribution indicating distribution beyond the plasma compartment, binding moderately to plasma proteins including albumin but minimally to sex hormone-binding globulin. Estradiol circulates largely bound to sex hormone-binding globulin (SHBG) and albumin, which affects its biological half-life and tissue distribution, particularly in hormone-sensitive tissues such as the uterus and breast. Norethindrone is extensively bound to albumin and has an extensive tissue distribution consistent with steroid hormones. The binding profiles influence pharmacodynamics and potential drug interactions. Distribution to central nervous system tissues is limited for these agents, which may mediate some of the adverse effect profiles, such as headache or mood changes.

Metabolism:
Elagolix undergoes hepatic metabolism primarily via cytochrome P450 enzyme CYP3A, with additional non-CYP mediated pathways contributing to its biotransformation. Estradiol is extensively metabolized in the liver to estrone and estriol, conjugated to glucuronides and sulfates, and undergoes enterohepatic recycling contributing to its hormonal activity duration. Norethindrone is metabolized mainly by hepatic reduction, hydroxylation, and conjugation pathways involving CYP3A4 enzymes. The metabolism of these components is subject to induction or inhibition by concomitant medications, potentially impacting plasma levels and clinical efficacy. Elagolix’s CYP3A metabolism is clinically significant since inhibitors or inducers of CYP3A may increase or decrease elagolix exposure, necessitating careful monitoring.

Elimination:
Elagolix is primarily eliminated via feces and urine as metabolites, with an elimination half-life ranging between 4 to 6 hours, explaining the need for twice-daily dosing. Estradiol metabolites are mainly excreted via the kidneys into the urine in conjugated forms; estradiol itself has a relatively short half-life but maintains effects due to metabolism and recirculation. Norethindrone elimination occurs predominantly through renal excretion after metabolism, with a half-life of approximately 8–10 hours. The elimination processes influence the dosing interval and duration of therapy. Renal or hepatic impairment may alter clearance rates, necessitating caution or dosage adjustments. Accumulation is not expected under standard dosing, but long-term use is limited to 24 months due to risks including bone loss.

Dosage Forms

Available Dosage Forms:
- Oriahnn is supplied as oral capsules intended for twice-daily administration with two distinct capsules: the white/yellow capsule and the white/blue capsule.
- The white/yellow capsule contains elagolix 300 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg.
- The white/blue capsule contains elagolix 300 mg only.

Dosages for Adults and Adolescents:
- The approved dosing regimen for adult premenopausal women with uterine fibroids involves taking one capsule orally twice daily (morning and evening).
- The morning dose consists of the combination capsule (elagolix, estradiol, norethindrone), and the evening dose consists of the elagolix only capsule.
- Therapy duration should not exceed 24 months due to the risk of bone mineral density loss.

Specific Patient Populations:
- Oriahnn is indicated exclusively for adult premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids).
- It is contraindicated in women who have reached menopause or have any contraindicating comorbidities like uncontrolled hypertension or hormone-sensitive cancers.
- Prior to initiation, pregnancy must be ruled out, as Oriahnn is contraindicated in pregnancy.
- Dose adjustments are not typically required based on hepatic or renal function, but caution is advised due to metabolism and elimination pathways.
- The drug is not approved or studied in pediatric populations or in male patients.

Mechanism Of Action

Oriahnn’s pharmacological effect arises from the coordinated action of its three components: elagolix, estradiol, and norethindrone. Elagolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland. This binding inhibits the pulsatile secretion of GnRH, leading to suppression of the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Consequently, this reduces ovarian production of estrogen and progesterone, which in turn diminishes stimulation of uterine fibroid growth and decreases heavy menstrual bleeding.

Estradiol, a form of estrogen included in Oriahnn, acts to mitigate the hypoestrogenic effects induced by elagolix, such as hot flashes and bone mineral density loss. By providing a low dose of estradiol, Oriahnn maintains a balance to prevent severe estrogen deficiency symptoms while still suppressing fibroid growth through the GnRH antagonist activity.

Norethindrone acetate, a progestin, further complements estradiol by stabilizing the endometrium, reducing menstrual bleeding, and preventing endometrial hyperplasia. The progestin also helps counterbalance estrogen’s proliferative effects on uterine lining cells. The combination mimics the protective effects of natural hormones, reducing adverse effects and improving tolerability.

Together, this triad achieves effective regulation of menstrual bleeding associated with uterine fibroids by suppressing the hormonal stimulation needed for fibroid proliferation and maintaining hormonal balance to minimize side effects. Clinical studies demonstrate significant reductions in bleeding volume and improvement in quality of life scores for patients with uterine leiomyomas. Compared to GnRH agonists, elagolix offers the advantage of rapid onset without the initial hormone flare, and combined hormonal add-back therapy allows longer treatment duration with reduced bone loss risk.

Pharmacological Actions

GnRH receptor antagonism leading to suppression of LH and FSH secretion
Reduction of ovarian estradiol and progesterone production to decrease uterine fibroid stimulation
Add-back hormonal therapy through estradiol to alleviate hypoestrogenic side effects
Progestin component stabilizes endometrial lining and reduces risk of endometrial hyperplasia
Reduction of heavy menstrual bleeding through hormonal modulation
Improvement of anemia symptoms secondary to fibroid-associated bleeding
Maintenance of bone mineral density through low-dose estradiol supplementation
Rapid onset of action compared to GnRH agonists without initial hormone surge
Modulation of menstrual cycle dynamics to reduce fibroid symptomatology
Minimal alteration of systemic hormone levels compared to full hormonal suppression therapies
Mitigation of menopausal-like symptoms commonly seen with GnRH antagonist monotherapy
Potential to improve fertility outcomes by controlling fibroid symptoms prior to conception efforts
Selective suppression of reproductive hormones without impacting other endocrine axes significantly
Dual capsule administration optimizing pharmacokinetics for sustained hormonal control
Improvement in quality of life measures related to heavy menstrual bleeding and fibroid symptoms

Therapeutic Or Clinical Uses

Management of heavy menstrual bleeding associated with uterine leiomyomas (uterine fibroids) in premenopausal adult women
Reduction of uterine fibroid-related symptoms including bleeding and anemia
Treatment option to delay or avoid surgical intervention in uterine fibroid cases
Hormonal therapy for fibroid-related menorrhagia unresponsive or contraindicated to other treatments
Adjunct therapy in fibroid patients with symptomatic anemia to improve hemoglobin levels
Non-surgical alternative for women seeking fertility preservation while controlling fibroid symptoms
Management of fibroid-associated symptoms to improve quality of life and daily functioning
Option for long-term management (up to 24 months) of heavy bleeding when surgery is not preferred
Treatment for patients with contraindications to estrogen-only or progestin-only therapies
Therapy targeting hormonal pathways specifically implicated in fibroid pathogenesis
Use in women who have not achieved menopause and require hormonal modulation for symptom control
Potential reduction in fibroid size through hormonal suppression, aiding subsequent surgical planning
Management of bleeding symptoms in patients intolerant to or not candidates for NSAIDs or tranexamic acid
Therapeutic alternative to GnRH agonists with reduced adverse effects and better tolerability
Indicated to improve menstrual cycle regularity and reduce irregular episodes associated with fibroids

Side Or Adverse Effects

Hot flashes due to hypoestrogenic state induced by GnRH antagonist activity
Fatigue or feeling tired as a systemic response to hormonal modulation
Hair loss, which may be permanent in some cases, linked to hormonal changes
Headache ranging from mild to severe, potentially related to vascular or endocrine effects
Irregular menstrual bleeding patterns including decreased or absent menstruation
Increased risk of blood clots (venous thromboembolism), stroke, or heart attack especially in older women or smokers
Gastrointestinal symptoms such as nausea or abdominal discomfort
Mood changes including depression, anxiety, or suicidal thoughts in susceptible individuals
Elevated blood sugar and symptoms suggestive of hyperglycemia in some patients
Possible liver or gallbladder dysfunction manifesting as jaundice or upper abdominal pain
Allergic reactions including hives, swelling of face, lips, tongue or throat, and difficulty breathing
Bone mineral density loss with prolonged therapy leading to osteoporosis risk
Breast tenderness or pain due to hormonal fluctuations
Increased blood pressure or worsening of existing hypertension
Visual disturbances or bulging eyes in rare cases

Precautions

Use only in premenopausal women with confirmed uterine fibroids and associated heavy menstrual bleeding
Evaluate bone mineral density prior to initiation and during therapy to monitor for bone loss
Pregnancy must be ruled out before starting Oriahnn; ensure effective nonhormonal contraception during treatment and for 28 days after discontinuation
Avoid use in women over 35 who smoke due to heightened cardiovascular risk
Monitor blood pressure regularly due to risk of hypertension exacerbation
Assess liver function tests periodically as drug may impact hepatic metabolism and function
Screen for history of thromboembolic events or clotting disorders prior to initiation
Be vigilant for symptoms of mood changes or depression; monitor mental health status
Discontinue therapy immediately if signs of cardiovascular events such as chest pain or neurological symptoms arise
Avoid coadministration with hormonal contraceptives or hormone replacement therapies
Advise patients on signs of possible allergic reactions and instruct reporting immediately
Use caution in patients with gallbladder disease or severe migraine history
Do not exceed 24 months of therapy due to cumulative risk for bone mineral density loss
Inform patients about possible menstrual changes that may obscure pregnancy detection
Educate patients to avoid grapefruit products as they may increase drug plasma concentrations

Warnings

Contraindicated in pregnancy due to potential risk of miscarriage and unknown fetal effects
Increased risk of serious cardiovascular events including blood clots, stroke, and heart attack
Higher risk of adverse cardiovascular effects in women over 35 who smoke or have pre-existing hypertension, diabetes, or hyperlipidemia
Bone loss may be partially irreversible; long-term use beyond 24 months is not recommended
Do not use in patients with hormone-sensitive cancers such as breast, uterine, cervical, or vaginal cancer
Should not be used in patients with active or history of thrombosis in heart, lungs, legs, or eyes
Avoid use in uncontrolled hypertension and severe migraine with aura
Use caution in patients with liver disease due to metabolism and clearance concerns
Discontinue immediately if patient develops chest pain, severe headache, vision changes, or unilateral leg swelling
Not effective as a form of contraception; pregnancy prevention requires nonhormonal methods
Avoid smoking during treatment to decrease risk of vascular events
Drug may interfere with certain lab tests; ensure healthcare providers are informed of Oriahnn use
If surgical procedures are planned, inform surgeon of current Oriahnn use due to clotting risk
Monitor for signs of liver dysfunction such as dark urine, jaundice, or clay-colored stools
Patients should be enrolled in pregnancy registries if pregnancy occurs during or shortly after therapy

Contraindication

Pregnancy or suspected pregnancy
Known hypersensitivity or allergy to elagolix, estradiol, norethindrone, or any components of the formulation
History of or current thromboembolic disorders including deep vein thrombosis, pulmonary embolism, myocardial infarction, or stroke
Uncontrolled hypertension
History of cerebrovascular disease or peripheral arterial disease
Active liver disease or impaired liver function
Hormone-sensitive malignancies such as breast, uterine, cervical, or vaginal cancers
Severe migraine headaches particularly with aura in women over 35 years
Smoking in women over 35 years of age
Undiagnosed abnormal vaginal bleeding
Osteoporosis or known bone mineral density disorders
History of heart valve disease or cardiac arrhythmias
Blood clotting disorders or coagulation abnormalities
Gallbladder disease
Diabetes with vascular complications (retinopathy, nephropathy, neuropathy)
Severe depression or mood disorders contraindicating hormonal therapy

Drug Interactions

CYP3A inhibitors may increase elagolix plasma concentrations, leading to enhanced effects and toxicity
CYP3A inducers may decrease elagolix efficacy by accelerating metabolism
Concurrent use with hormonal contraceptives is contraindicated due to overlapping hormonal effects
Additive effects on increased risk of thromboembolism when combined with other estrogen-containing products
Drug interactions with corticosteroid replacement therapy may alter steroid metabolism
Thyroid medications may interact, necessitating dose adjustments and monitoring thyroid function
Grapefruit or grapefruit juice ingestion may increase plasma levels of Oriahnn components via CYP3A inhibition
Potential interactions with anticoagulants require close monitoring of coagulation parameters
Use caution when combined with other medications that affect liver enzymes or hepatic blood flow
Concurrent use with enzyme-inducing antiepileptics may reduce Oriahnn efficacy
Avoid concomitant use with St. John's Wort and other herbal inducers of CYP enzymes
Co-administration with medications metabolized by CYP3A4 may either inhibit or compete affecting plasma levels
NSAIDs and other drugs affecting hemostasis should be used cautiously due to increased bleeding risk
Vitamin D and calcium supplementation is recommended to manage bone loss during therapy
Monitor blood glucose levels if used concurrently with antidiabetic agents due to potential alterations in glucose metabolism

Preparations Of The Drug

Oral capsules containing fixed-dose combination of elagolix, estradiol, and norethindrone acetate
Two distinct oral capsules per dosing regimen: morning capsule (elagolix 300 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) and evening capsule (elagolix 300 mg)
Packaged for twice-daily administration with clear color differentiation to aid compliance
Supplied in blister packs or bottles to protect capsules from moisture and ensure stability
Storage at room temperature away from moisture, heat, and direct light recommended
Not formulated for parenteral, topical, or other routes of administration
Accompanied by detailed patient medication guides due to risk profile and need for adherence
May be co-prescribed with vitamin D and calcium supplements during therapy
Available only by prescription for use under specialist gynecological supervision
Includes patient counseling information for pregnancy prevention and management of side effects
Manufactured under strict quality control ensuring consistent dosing and bioavailability
Not intended for over-the-counter use or unsupervised administration
Proper disposal through drug take-back programs recommended; capsules should not be flushed
Capsules contain inactive ingredients safe for oral administration without known allergenic potential
Packaged with dosing instructions emphasizing twice-daily intake to maintain steady-state hormone levels